Overview

A Bioequivalence Study With Clinical Endpoints to Evaluate the Safety and Therapeutic Equivalence of Permethrin Cream 5% & Elimite™ in Subjects With Scabies

Status:
Completed

Trial end date:
2018-12-06

Target enrollment:

Participant gender:

Summary

This phase III study was conducted to establish the clinical bioequivalence of Permethrin Cream 5% and Elimite™ in the treatment of scabies following a single application.

Phase:

Phase 3

Details

Lead Sponsor:

bioRASI, LLC
Saptalis Pharmaceuticals LLC

Collaborators:

bioRASI, LLC
Saptalis Pharmaceuticals

Treatments:

Permethrin